Download PDF
Suchttherapie 2005; 6(2): 66-69
DOI: 10.1055/s-2005-858335
Originalarbeit

© Georg Thieme Verlag KG Stuttgart · New York

Therapie der chronischen Hepatitis C bei Patienten mit psychischen Erkrankungen

Treatment of Chronic Hepatitis C in Mentally Ill PatientsM. Schäfer1
  • 1Klinik für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin
Further Information

Publication History

Publication Date:
22 June 2005 (online)

Also available at
   Permissions and Reprints

Zusammenfassung

70 - 90 % der Patienten mit einer intravenösen Drogenabhängigkeit sind chronisch mit dem Hepatitis-C-Virus (HCV) infiziert und haben eine Indikation zur antiviralen Therapie mit pegyliertem Interferon-α plus Ribavirin. Eine bei dieser Patientengruppe jedoch häufig vorhandene psychiatrische Komorbidität stellt bei den zahlreichen möglichen psychischen Nebenwirkungen des Interferon- α eine zumindest relative Kontraindikation dar, aufgrund derer die Patienten immer noch häufig von einer Therapie ausgeschlossen werden. Die in diesem Artikel zusammengefasste aktuelle Studienlage zeigt jedoch, dass auch bei Patienten mit einer Drogenabhängigkeit und psychischen Störungen während der HCV-Therapie gleiche Ansprechraten und gute Haltequoten erreicht werden können, wenn die Patienten interdisziplinär betreut werden. Nur schwere und aktuell exazerbierte psychiatrische Krankheitsbilder sollten daher Kontraindikationen gegen eine Therapie mit Interferon- α darstellen.

Abstract

70 - 90 % of intravenous drug users are chronically infected with the hepatitis C virus and would need antiviral treatment with pegylated interferon- α and ribavirin. However, because interferon- α can induce severe psychiatric side effects, especially the presence of psychiatric comorbidities often tends to result in an exclusion from the otherwise helpful antiviral treatment. Recent trials about hepatitis C treatment for intravenous drug users demonstrate that response rates and adherence do not significantly differ between patients with or without drug addiction, even in case of psychiatric disorders, if patients are treated in an interdisciplinary setting. Thus, only severe and unstable psychiatric conditions should still be regarded as contraindication against antiviral treatment with interferon- α.

Schlüsselwörter

Hepatitis C - Interferon-α - psychische Störungen - Drogenabhängigkeit - Nebenwirkungen

Key words

Hepatitis C - Interferon-α - psychiatric disorders - drug addiction - side-effects

Literatur

  • 1 Lynch P, Peters M, Quigley M. et al . Impact of psychiatric disorders on treatment of patients with hepatitis C.  Gastroenterol. 1998;  114 (Suppl.) A1294
    PubMedGoogle Scholar
  • 2 Shad J, Person J, Brann O. How often are referred chronic hepatitis C patients candidates for antiviral therapy.  Hepatology. 2000;  32 A283
    PubMedGoogle Scholar
  • 3 Taruschio G, Santarini G, Sica G. Psychiatric disorders in hepatitis C virus related chronic liver disease.  Gastroenterology. 1996;  110 A1342
    PubMedGoogle Scholar
  • 4 Taylor L E, Costello T, Alt E. et al . Psychiatric illness and illicit drugs as barriers to hepatitis C treatment among HIV/hepatitis C virus co-infected individuals.  AIDS. 2002;  16 (12) 1700-1701
    CrossrefPubMedGoogle Scholar
  • 5 Dinwiddie S H, Shicker L, Newman T. Prevalence of hepatitis C among psychiatric patients in the public sector.  Am J Psychiatry. 2003;  160 (1) 172-174
    Google Scholar
  • 6 Cividini A, Pistorio A, Regazzetti A. et al . Hepatitis C virus infection among institutionalised psychiatric patients: a regression analysis of indicators of risk.  J Hepatol. 1997;  27 (3) 455-463
    CrossrefPubMedGoogle Scholar
  • 7 Chang T T, Lin H, Yen Y S. et al . Hepatitis B and hepatitis C among institutionalized psychiatric patients in Taiwan.  J Med Virol. 1993;  40 (2) 170-173
    PubMedGoogle Scholar
  • 8 Schaefer M, Engelbrecht M A, Gut O. et al . Interferon alpha (IFNalpha) and psychiatric syndromes: a review.  Prog Neuropsychopharmacol Biol Psychiatry. 2002;  26 (4) 731-746
    CrossrefPubMedGoogle Scholar
  • 9 McDonald E M, Mann A H, Thomas H C. Interferons as mediators of psychiatric morbidity. An investigation in a trial of recombinant alpha-interferon in hepatitis-B carriers.  Lancet. 1987;  2 (8569) 1175-1178
    PubMedGoogle Scholar
  • 10 Renault P F, Hoofnagle J H, Park Y. et al . Psychiatric complications of long-term interferon alfa therapy.  Arch Intern Med. 1987;  147 (9) 1577-1580
    CrossrefPubMedGoogle Scholar
  • 11 Renault P F, Hoofnagle J H. Side effects of alpha interferon.  Semin Liver Dis. 1989;  9 (4) 273-277
    PubMedGoogle Scholar
  • 12 Valentine A D, Meyers C A, Kling M A. et al . Mood and cognitive side effects of interferon-alpha therapy.  Semin Oncol. 1998;  25 (1 Suppl 1) 39-47
    PubMedGoogle Scholar
  • 13 Dieperink E, Willenbring M, Ho S B. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review.  Am J Psychiatry. 2000;  157 (6) 867-876
    CrossrefPubMedGoogle Scholar
  • 14 Schaefer M, Schmidt F, Folwaczny C. et al . Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups.  Hepatology. 2003;  37 (2) 443-451
    CrossrefPubMedGoogle Scholar
  • 15 Janssen H L, Brouwer J T, van der Mast R C. et al . Suicide associated with alfa-interferon therapy for chronic viral hepatitis.  J Hepatol. 1994;  21 (2) 241-243
    CrossrefPubMedGoogle Scholar
  • 16 Van Thiel D H, Friedlander L, Molloy P J. et al . Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness.  Eur J Gastroenterol Hepatol. 1995;  7 (2) 165-168
    PubMedGoogle Scholar
  • 17 Van Thiel D H, Anantharaju A, Creech S. Response to treatment of hepatitis C in individuals with a recent history of intravenous drug abuse.  Am J Gastroenterol. 2003;  98 (10) 2281-2288
    PubMedGoogle Scholar
  • 18 Pariante C M, Orru M G, Baita A. et al . Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders.  Lancet. 1999;  354 (9173) 131-132
    CrossrefPubMedGoogle Scholar
  • 19 Pariante C M, Landau S, Carpiniello B. Interferon alfa-induced adverse effects in patients with a psychiatric diagnosis.  N Engl J Med. 2002;  347 (2) 148-149
    CrossrefPubMedGoogle Scholar
  • 20 Schaefer M, Schmidt F, Horn M. et al . Depression during treatment with interferon alpha.  Psychosomatics. 2004;  45 (2) 176
    CrossrefPubMedGoogle Scholar
  • 21 Capuron L, Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient’s initial affective state.  N Engl J Med. 1999;  340 (17) 1370
    PubMedGoogle Scholar
  • 22 Sylvestre D L. Treating hepatitis C in methadone maintenance patients: an interim analysis.  Drug Alcohol Depend. 2002;  67 (2) 117-123
    CrossrefPubMedGoogle Scholar
  • 23 Cabrera Gomez J A Jr, Cordero G, Fernandez L O. et al . Treatment of schizophrenic disorder, paranoid type, with intramuscular recombinant alpha-2 b interferon.  Biotherapy. 1993;  7 (1) 27-37
    CrossrefPubMedGoogle Scholar
  • 24 Dobmeier M, Frick E, Frank S. et al . Schizophrenic psychosis: a contraindication for treatment of hepatitis C with interferon alpha?.  Pharmacopsychiatry. 2000;  33 (2) 72-74
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Schafer M, Boetsch T, Laakmann G. Psychosis in a methadone-substituted patient during interferon-alpha treatment of hepatitis C.  Addiction. 2000;  95 (7) 1101-1104
    CrossrefPubMedGoogle Scholar
  • 26 Schafer M, Schmidt F, Grunze H. et al . [Interferon alpha-associated agranulocytosis during clozapine treatment. Case report and status of current knowledge].  Nervenarzt. 2001;  72 (11) 872-875
    CrossrefPubMedGoogle Scholar
  • 27 Musselman D L, Lawson D H, Gumnick J F. et al . Paroxetine for the prevention of depression induced by high-dose interferon alfa.  N Engl J Med. 2001;  344 (13) 961-966
    CrossrefPubMedGoogle Scholar
  • 28 Schäfer M. Hepatitis-C-Therapie: Management psychiatrischer Nebenwirkungen von Interferon alfa. Stuttgart, New York; Georg Thieme Verlag 2004
    Google Scholar
  • 29 Schafer M, Schwaiger M. [Incidence, pathoetiology and treatment of interferon-alpha induced neuro-psychiatric side effects].  Fortschr Neurol Psychiatr. 2003;  71 (9) 469-476
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Anand B S, Velez M. Influence of chronic alcohol abuse on hepatitis C virus replication.  Dig Dis. 2000;  18 (3) 168-171
    CrossrefPubMedGoogle Scholar
  • 31 Anderson S, Nevins C L, Green L K. et al . Assessment of liver histology in chronic alcoholics with and without hepatitis C virus infection.  Dig Dis Sci. 2001;  46 (7) 1393-1398
    CrossrefPubMedGoogle Scholar
  • 32 Bhattacharya R, Shuhart M C. Hepatitis C and alcohol: interactions, outcomes, and implications.  J Clin Gastroenterol. 2003;  36 (3) 242-252
    CrossrefPubMedGoogle Scholar
  • 33 Jamal M M, Morgan T R. Liver disease in alcohol and hepatitis C.  Best Pract Res Clin Gastroenterol. 2003;  17 (4) 649-662
    CrossrefPubMedGoogle Scholar
  • 34 Peters M G, Terrault N A. Alcohol use and hepatitis C.  Hepatology. 2002;  36 (5 Suppl 1) S220-S225
    CrossrefPubMedGoogle Scholar
  • 35 Zhang T, Li Y, Lai J P. et al . Alcohol potentiates hepatitis C virus replicon expression.  Hepatology. 2003;  38 (1) 57-65
    CrossrefPubMedGoogle Scholar

Martin Schäfer

Klinik für Psychiatrie und Psychotherapie, Charité - Universitätsmedizin Berlin, Campus Charité Mitte

Schumannstr. 20/21

10117 Berlin

Email: martin.schaefer@charite.de

      >